<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03149796</url>
  </required_header>
  <id_info>
    <org_study_id>CMC-11-0018-CTIL</org_study_id>
    <nct_id>NCT03149796</nct_id>
  </id_info>
  <brief_title>Tocilizumab Effect on microRNA Expression and Adipokine Levels in Rheumatoid Arthritis Patients</brief_title>
  <official_title>The Effect of Tocilizumab (Anti-interleukin-6) Treatment on microRNA Expression and Adipokine Levels in Rheumatoid Arthritis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carmel Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Carmel Medical Center</source>
  <brief_summary>
    <textblock>
      The investigators propose to identify changes in cytokines like adipocytokines and microRNA
      (miR) expression (for example miR-9, miR-16, miR-125, miR-132, miR-146a, miR-150, miR-155,
      miR-181 and miR-223) in peripheral blood leukocytes and in serum samples obtained from
      rheumatoid arthritis (RA) patients before and after tocilizumab treatment. The results
      obtained will be compared to gender- and age-matched healthy controls, and will help the
      investigators define one or more miRNAs as biomarkers for treatment effectiveness.

      Methods The investigators will obtain blood samples from 60 RA patients treated with
      tocilizumab, according to the local clinical guidelines. Blood samples will be collected
      before treatment, as well as one and four months following tocilizumab treatment. The blood
      samples will initially undergo microarray analysis and then the results will be confirmed for
      specific miRNAs by quantitative real-time PCR (qPCR). The serum level of the tested
      cytokines, like adipokines, will be measured using ELISA methods. The changes in cytokines
      level and miRNAs expression, either up-regulation or down-regulation, during tocilizumab
      therapy will be correlated to the severity of the disease and to specific demographic and
      medical data. The results obtained will be compared to 60 healthy controls gender- and
      age-matched
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the study is to investigate the effects of tocilizumab on the expression of
      biomarkers like adipocytokines and miRNAs in peripheral blood leukocytes and in serum samples
      obtained from rheumatoid arthritis patients. Candidate miRNAs that are likely to be
      quantitated are for example miR-9, 16, 125, 132, 146a, 150, 155, 181 and, 223. The results
      obtained will help the investigators determine if cytokines and miRNAs expression can be used
      as a novel biomarker for the determination of the effectiveness of tocilizumab treatment.

      The study is designed as a prospective study investigating the effect of tocilizumab on the
      expression of cytokines and miRNA in rheumatoid arthritis patients. Sixty rheumatoid
      arthritis patients designated to be treated with tocilizumab and followed in rheumatology
      clinics.

      After receiving informed consent, three blood samples of 5cc blood each will be drawn: the
      first - before tocilizumab treatment to set the basal level of expression in untreated
      patients, the second and third samples will be taken one month and four months after
      initiation of tocilizumab treatment. The investigators will use selected samples (from 5
      patients) to perform microarray analysis for miRNAs expression, and based on the results, we
      will confirm the expression of specific miRNAs by quantitative real-time PCR (qPCR). Based on
      current knowledge, the investigators expect that miR-9, 16, 125, 132, 146a, 150, 155, 181
      and, 223 will show significant changes in expression upon tocilizumab treatment. Cytokines
      levels are measured using ELISA tests for each individual biomarker. The changes in cytokines
      and miRNAs expression, either up-regulation or down-regulation, will be correlated to the
      severity of the disease and to the clinical effect of tocilizumab. Information regarding
      disease duration, activity as measured by disease activity score, concomitant treatment and
      serology status will be collected. Also demographic characteristics - age, sex and smoking
      status will be recorded. The results will be compared to 60 healthy controls gender- and age
      matched, without any rheumatic, inflammatory or malignant disorders
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 23, 2011</start_date>
  <completion_date type="Actual">May 1, 2013</completion_date>
  <primary_completion_date type="Actual">May 1, 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>expression of biomarkers like adipocytokines and miRNAs</measure>
    <time_frame>four months</time_frame>
    <description>expression of biomarkers like adipocytokines and miRNAs in peripheral blood leukocytes and in serum samples obtained from RA patients. Candidate miRNAs that are likely to be quantitated are for example miR-9, 16, 125, 132, 146a, 150, 155, 181 and, 223</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">80</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>RA patients</arm_group_label>
    <description>designated to be treated with tocilizumab and followed in rheumatology clinics.
Laboratory blood tests will be collected and analyzed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy controls</arm_group_label>
    <description>control Laboratory blood tests will be collected and analyzed</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory blood tests</intervention_name>
    <description>Serum concentrations of leptin, adiponectin, resistin, interleukin-6 and high sensitivity C reactive protein were measured by ELISA in both study groups</description>
    <arm_group_label>RA patients</arm_group_label>
    <arm_group_label>healthy controls</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      periferal blood and serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        RA patients treated with tocilizumab, according to the local clinical guidelines
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients fulfilling the 2010 Rheumatoid Arthritis Classification criteria.

          -  Patients designated to tocilizumab treatment

          -  Age above 18 years old

          -  Signed informed concern

          -  Ability to read and write in Hebrew

        Exclusion Criteria:

          -  Patients with other rheumatic diseases

          -  Patients with other inflammatory diseases

          -  Patients with malignancies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <reference>
    <citation>Barton A, Worthington J. Genetic susceptibility to rheumatoid arthritis: an emerging picture. Arthritis Rheum. 2009 Oct 15;61(10):1441-6. doi: 10.1002/art.24672. Review.</citation>
    <PMID>19790122</PMID>
  </reference>
  <reference>
    <citation>Symmons D, Harrison B. Early inflammatory polyarthritis: results from the norfolk arthritis register with a review of the literature. I. Risk factors for the development of inflammatory polyarthritis and rheumatoid arthritis. Rheumatology (Oxford). 2000 Aug;39(8):835-43. Review.</citation>
    <PMID>10952736</PMID>
  </reference>
  <reference>
    <citation>Lard LR, Visser H, Speyer I, vander Horst-Bruinsma IE, Zwinderman AH, Breedveld FC, Hazes JM. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med. 2001 Oct 15;111(6):446-51.</citation>
    <PMID>11690569</PMID>
  </reference>
  <reference>
    <citation>Firestein GS. Evolving concepts of rheumatoid arthritis. Nature. 2003 May 15;423(6937):356-61. Review.</citation>
    <PMID>12748655</PMID>
  </reference>
  <reference>
    <citation>Redlich K, Hayer S, Ricci R, David JP, Tohidast-Akrad M, Kollias G, Steiner G, Smolen JS, Wagner EF, Schett G. Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest. 2002 Nov;110(10):1419-27.</citation>
    <PMID>12438440</PMID>
  </reference>
  <reference>
    <citation>Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996;14:397-440. Review.</citation>
    <PMID>8717520</PMID>
  </reference>
  <reference>
    <citation>Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, Saito S, Inoue K, Kamatani N, Gillespie MT, Martin TJ, Suda T. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest. 1999 May;103(9):1345-52.</citation>
    <PMID>10225978</PMID>
  </reference>
  <reference>
    <citation>Dayer JM, Choy E. Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology (Oxford). 2010 Jan;49(1):15-24. doi: 10.1093/rheumatology/kep329. Epub 2009 Oct 23. Review.</citation>
    <PMID>19854855</PMID>
  </reference>
  <reference>
    <citation>Eastgate JA, Symons JA, Wood NC, Grinlinton FM, di Giovine FS, Duff GW. Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis. Lancet. 1988 Sep 24;2(8613):706-9.</citation>
    <PMID>2901567</PMID>
  </reference>
  <reference>
    <citation>van Leeuwen MA, Westra J, Limburg PC, van Riel PL, van Rijswijk MH. Clinical significance of interleukin-6 measurement in early rheumatoid arthritis: relation with laboratory and clinical variables and radiological progression in a three year prospective study. Ann Rheum Dis. 1995 Aug;54(8):674-7.</citation>
    <PMID>7677445</PMID>
  </reference>
  <reference>
    <citation>Taganov KD, Boldin MP, Baltimore D. MicroRNAs and immunity: tiny players in a big field. Immunity. 2007 Feb;26(2):133-7. Review.</citation>
    <PMID>17307699</PMID>
  </reference>
  <reference>
    <citation>Shi XB, Tepper CG, deVere White RW. Cancerous miRNAs and their regulation. Cell Cycle. 2008 Jun 1;7(11):1529-38. Epub 2008 Mar 20. Review.</citation>
    <PMID>18469525</PMID>
  </reference>
  <reference>
    <citation>Williams AE, Perry MM, Moschos SA, Larner-Svensson HM, Lindsay MA. Role of miRNA-146a in the regulation of the innate immune response and cancer. Biochem Soc Trans. 2008 Dec;36(Pt 6):1211-5. doi: 10.1042/BST0361211. Review.</citation>
    <PMID>19021527</PMID>
  </reference>
  <reference>
    <citation>Baltimore D, Boldin MP, O'Connell RM, Rao DS, Taganov KD. MicroRNAs: new regulators of immune cell development and function. Nat Immunol. 2008 Aug;9(8):839-45. doi: 10.1038/ni.f.209. Review.</citation>
    <PMID>18645592</PMID>
  </reference>
  <reference>
    <citation>O'Connell RM, Taganov KD, Boldin MP, Cheng G, Baltimore D. MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci U S A. 2007 Jan 30;104(5):1604-9. Epub 2007 Jan 22.</citation>
    <PMID>17242365</PMID>
  </reference>
  <reference>
    <citation>Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12481-6. Epub 2006 Aug 2.</citation>
    <PMID>16885212</PMID>
  </reference>
  <reference>
    <citation>Luo X, Tsai LM, Shen N, Yu D. Evidence for microRNA-mediated regulation in rheumatic diseases. Ann Rheum Dis. 2010 Jan;69 Suppl 1:i30-36. doi: 10.1136/ard.2009.117218. Review.</citation>
    <PMID>19995741</PMID>
  </reference>
  <reference>
    <citation>Pauley KM, Satoh M, Chan AL, Bubb MR, Reeves WH, Chan EK. Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Res Ther. 2008;10(4):R101. doi: 10.1186/ar2493. Epub 2008 Aug 29.</citation>
    <PMID>18759964</PMID>
  </reference>
  <reference>
    <citation>Meng F, Henson R, Wehbe-Janek H, Smith H, Ueno Y, Patel T. The MicroRNA let-7a modulates interleukin-6-dependent STAT-3 survival signaling in malignant human cholangiocytes. J Biol Chem. 2007 Mar 16;282(11):8256-64. Epub 2007 Jan 12.</citation>
    <PMID>17220301</PMID>
  </reference>
  <reference>
    <citation>Trenkmann M, Brock M, Ospelt C, Gay S. Epigenetics in rheumatoid arthritis. Clin Rev Allergy Immunol. 2010 Aug;39(1):10-9. doi: 10.1007/s12016-009-8166-6. Review.</citation>
    <PMID>19707891</PMID>
  </reference>
  <reference>
    <citation>Lotvall J, Valadi H. Cell to cell signalling via exosomes through esRNA. Cell Adh Migr. 2007 Jul-Sep;1(3):156-8. Epub 2007 Jul 4. Review.</citation>
    <PMID>19262134</PMID>
  </reference>
  <reference>
    <citation>Rho YH, Solus J, Sokka T, Oeser A, Chung CP, Gebretsadik T, Shintani A, Pincus T, Stein CM. Adipocytokines are associated with radiographic joint damage in rheumatoid arthritis. Arthritis Rheum. 2009 Jul;60(7):1906-14. doi: 10.1002/art.24626.</citation>
    <PMID>19565493</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2017</study_first_submitted>
  <study_first_submitted_qc>May 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2017</study_first_posted>
  <last_update_submitted>May 14, 2017</last_update_submitted>
  <last_update_submitted_qc>May 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Carmel Medical Center</investigator_affiliation>
    <investigator_full_name>Devy Zissman</investigator_full_name>
    <investigator_title>head of rheumatology department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

